关于我们
OUR ENTERPRISEFounded in 2013, Zhejiang Wenda Medical Technology Co., Ltd. is a high-tech enterprise specializing in new drug discovery and development. At present, the company is located in Room 301, Building 3, Yinhai Science and Technology Innovation Center, No.501 Fucheng Road, Xiasha Street, Qiantang District, Hangzhou City, Zhejiang Province . The products under development include new drugs for a variety of cancers and autoimmune diseases, and a number of products have entered phase I and phase II trials.
科研
SCIENCE
WD-890: TYK2抑制剂目前在临床一期。
WD-910：透脑性抑制剂预计2024年年底进入临床。
WD-920：透脑的高选择性抑制剂预计在2025年进入临床申报。
WD-930: 透脑的高选择性抑制剂预计在2025年进入临床申报。
WD-940：透脑的突变抑制剂预计2025年进入临床申报。
NHWD-870: BET inhibitorisinthesecondphasetrial.
WD-890: TYK2 inhibitor is in the first phase trial.
WD-910：Brain-penetrating inhibitor planned to enter clinical trial in 2024.
WD-920：Brain-penetrating inhibitor is expected to enter clinical trial in 2025.
WD-930：Brain-penetrating inhibitor is expected to enter clinical trial in 2025.
WD-940：Brain-penetrating inhibitor is expected to enter clinical trial in 2025.
管线
PIPELINE
浙江足球赌注软件以满足临床需求为导向来开发自己拥有全球知识产权的高质量化合物。
1：NHWD-870 晚期癌症研究进展，目前在临床二期。
2：WD-890 银屑病关节炎，红斑狼疮，肠炎等适应症，目前在临床一期。
3: WD-910 多发性硬化症，痴呆症。
4：WD-920 渐冻症，帕金森。
5：WD-930 肿瘤。
6：WD-940 肿瘤。
Zhejiang Wenda develops its own high-quality compounds with global intellectual property.
1. NHWD-870 Advanced cancer, in the second phase trial.
2. WD-890 Indications such as psoriatic arthritis, lupus erythematosus and enteritis, etc, in the first phase trial .
3. WD-910 Multiple sclerosis, dementia
4. WD-920 ALS, Parkinson's disease.
5. WD-930 Advanced cancer.
6: WD-940 Advanced cancer.
| 项目名称/代号 | 靶点 | 适应症 | 研究进展 | 上市 | |||||
|---|---|---|---|---|---|---|---|---|---|
| 化合物筛选 | 临床前 | IND | I期 | II期 | III期 | ||||
| NHWD-870 | BET抑制剂 | 中线癌(NUT) | |||||||
| 非霍奇金淋巴瘤 | |||||||||
| WD-890 | TYK2(JH2)抑制剂 | 红斑狼疮、银屑病、银屑病关节炎 | |||||||
| WD-910 | NA | 多发性硬化症，痴呆症 | |||||||
| WD-920 | NA | 渐冻症，帕金森 | |||||||
| WD-930 | NA | 肿瘤 | |||||||
| WD-940 | NA | HER2/HER2 20ins突变型肿瘤 | |||||||
